Inovio Pharmaceuticals (INO) Debt to Equity (2016 - 2025)
Inovio Pharmaceuticals (INO) has disclosed Debt to Equity for 16 consecutive years, with $1.21 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 523.42% to $1.21 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.21 through Dec 2025, up 523.42% year-over-year, with the annual reading at $1.21 for FY2025, 523.42% up from the prior year.
- Debt to Equity hit $1.21 in Q4 2025 for Inovio Pharmaceuticals, up from -$6.53 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.21 in Q4 2025 to a low of -$6.53 in Q3 2025.
- Historically, Debt to Equity has averaged -$0.29 across 5 years, with a median of $0.01 in 2022.
- Biggest five-year swings in Debt to Equity: tumbled 55.82% in 2021 and later skyrocketed 2093.56% in 2023.
- Year by year, Debt to Equity stood at $0.0 in 2021, then soared by 346.76% to $0.01 in 2022, then soared by 1848.13% to $0.12 in 2023, then surged by 62.13% to $0.19 in 2024, then soared by 523.42% to $1.21 in 2025.
- Business Quant data shows Debt to Equity for INO at $1.21 in Q4 2025, -$6.53 in Q3 2025, and $0.4 in Q2 2025.